AVITA Medical, Inc. (RCEL)

Market Cap	118.62M
Revenue (ttm)	72.40M
Net Income (ttm)	-48.56M
Shares Out	30.49M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,278
Open	3.750
Previous Close	3.750
Day's Range	3.750 - 3.930
52-Week Range	3.350 - 14.160
Beta	1.65
Analysts	Buy
Price Target	11.75 (+202.06%)
Earnings Date	Nov 6, 2025

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cary Vance
• Employees: 260
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL
• Website: https://avitamedical.com

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price target is $11.75, which is an increase of 202.06% from the latest price.

Price Target

$11.75

(202.06% upside)

Analyst Consensus: Buy